- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04973020
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
November 25, 2021 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Single-centre, Single-dose, Open-label and Self-control Study to Evaluate the Effect of Efavirenz on Pharmacokinetic of SHR6390 in Healthy Chinese Subjects
The study is a single-center, open, single-dose, self-controlled clinical trial.
It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Xuanwu Hospital Beijing, Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent;
- Healthy subjects aged 18~45 (including 18 and 45 years old);
- Male body weight ≥ 50kg, female body weight ≥ 45kg, body mass index (BMI) within the range of 19 ~ 26kg /m2 (including 19 and 26 kg/m2) (BMI= weight (kg)/height 2 (m2));
- The subjects had no fertility plan, took effective contraceptive measures voluntarily, and could not donate sperm or eggs within 7 months after signing the informed consent form to the last medication; the serum HCG test of women with fertility must be negative before the study medication.
Exclusion Criteria:
- Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results.
- Those who have undergone surgery within 6 months before the trial, or plan to perform surgery during the study period;
- Those who donated blood or suffered heavy blood loss (≥400 mL), received blood transfusions, or used blood products within 3 months before enrollment;
- Have a history of allergies to drugs, food or other substances;
- Those who have used soft drugs (such as marijuana) within 3 months before the test or hard drugs (such as cocaine, phencyclidine, etc.) within 1 year before the test; Those with positive results in urine drug abuse screening;
- Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration;
- Those who have taken any medicine within 4 weeks before the first administration (including prescription medicines, non-prescription medicines, Chinese herbal medicines, vitamins, calcium tablets and other food supplements), especially the drugs which have any effect on CYP3A4;
- Regular drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine), and any alcohol-containing products cannot be stopped during the study Those who are positive for alcohol breath test;
- Those with any abnormal result (clinically significant) of vital signs, physical examination, 12-lead electrocardiogram, chest radiograph, abdominal ultrasound, colour Doppler echocardiography, hematology, clinical chemistry, urinalysis and coagulation;
- Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is positive, or treponema pallidum antibody is positive, or human immunodeficiency virus antibody is positive.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment group
|
SHR6390 tablet single dose;Efavirenz single dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tmax
Time Frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
Time to maximum observed serum concentration (Tmax) for SHR6390 after Single dose.
|
from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
|
Cmax
Time Frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
Maximum observed serum concentration (Cmax)for SHR6390 after Single dose.
|
from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
|
AUC0-t
Time Frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose.
|
from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
|
AUC0-inf
Time Frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR6390 after Single dose.
|
from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
|
T1/2
Time Frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
Time to elimination half-life (T1/2) for for SHR6390 after Single dose.
|
from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of subjects with adverse events and severity of adverse events
Time Frame: from Day 1 to Day 34 after the first dose
|
from Day 1 to Day 34 after the first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Actual)
October 28, 2021
Study Completion (Actual)
October 28, 2021
Study Registration Dates
First Submitted
July 11, 2021
First Submitted That Met QC Criteria
July 20, 2021
First Posted (Actual)
July 22, 2021
Study Record Updates
Last Update Posted (Actual)
November 29, 2021
Last Update Submitted That Met QC Criteria
November 25, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Efavirenz
Other Study ID Numbers
- SHR6390-I-111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.